News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immusol, Inc. Announces An Exclusive Worldwide License Agreement With Baylor College of Medicine For A Novel Cancer Therapy


2/1/2006 2:54:25 PM

SAN DIEGO--(BUSINESS WIRE)--Feb. 1, 2006--Immusol announced today that it has entered into a license agreement with Baylor College of Medicine for the exclusive, worldwide rights to a novel oncolytic viral therapy using herpes simplex viruses. Baylor researchers have developed extensive expertise in the field of oncolytic virotherapies against a wide variety of solid tumors. The in-licensed therapy represents Baylor's most advanced virotherapy to date and has shown safety and strong efficacy in a number of preclinical animal tumor models. The financial terms of the license agreement were not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES